Accelerate Diagnostics, Inc. is in vitro diagnostics company engaged in providing solutions for the global challenges of antibiotic resistance and sepsis. Its Accelerate Pheno system and Accelerate PhenoTest BC kit combine several technologies aimed at reducing the time clinicians must wait to determine the optimal antibiotic therapy for infections. The Accelerate PhenoTest BC Kit, which is the test kit for the system, is indicated as an aid, in conjunction with other clinical and laboratory findings, in the diagnosis of bacteremia and fungemia, both life-threatening conditions with high morbidity and mortality risk. The device provides identification (ID) results followed by antibiotic susceptibility testing (AST) for certain pathogenic bacteria commonly associated with or causing bacteremia. Its other products include Accelerate Pheno system and BC kit, Accelerate Arc system and BC Kit (Accelerate Arc Products), and Accelerate Wave system.
Unternehmens-codeAXDX
Name des UnternehmensAccelerate Diagnostics Inc
IPO-datumOct 27, 1993
Gegründet am2012
CEOMr. John (Jack) Phillips
Anzahl der mitarbeiter107
WertpapierartOrdinary Share
GeschäftsjahresendeOct 27
Addresse3950 S Country Club Rd Ste 470 Bldg 3-307
StadtDENVER
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl80203
Telefon13038638088
Websitehttps://acceleratediagnostics.com/
Unternehmens-codeAXDX
IPO-datumOct 27, 1993
Gegründet am2012
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten